tbuckley/cabot-search huggingface dataset:
Efficiently Inhibiting Systemic Inflammatory Cascades by Fullerenes for Retarding HFD‐Fueled Atherosclerosis
Authors: Sheng'e Su, Mingming Zhen, Chen Zhou, Xinran Cao, Zihao Sun, Yuan Xu, Lei Li, Wang Jia, Zhanfeng Wu, Chunru Wang
Journal: Advanced Healthcare Materials (2023)

Abstract Atherosclerosis accounts for major mortality of cardiac‐cerebral vascular diseases worldwide. Pathologically, persistent inflammation dominates the progression of atherosclerosis, which can be accelerated by a high‐fat diet (HFD), possibly through triggering local intestinal oxidative stress and ensuing gut barrier dysfunction. Current pharmacotherapy has been disappointing, ascribed to limited therapeutic efficacy and undesirable side effects. Hence it is compelling to explore novel efficient anti‐atherosclerotic drugs with minimal toxicity. Herein, two fullerene‐based therapies with exceptional antioxidant capacity, in the form of water‐soluble injectable fullerene nanoparticles (IFNPs) and oral fullerene tablets (OFTs), are demonstrated to retard HFD‐fueled atherosclerosis in ApoE −/‐ mice with favorable biosafety. Especially, OFTs afford robust anti‐atherosclerotic therapeutic even against advanced plaques, besides stabilizing plaques with less lipid deposition and improved collagen expression. Specifically, it is identified that OFTs can ameliorate HFD‐induced dysregulated intestinal redox homeostasis and restore gut barrier integrity, thereby restraining the translocation of luminal lipopolysaccharide (LPS) into the bloodstream. Furthermore, significantly reduced circulating LPS after OFTs treatment contributes to down‐regulated LPS/TLR4/NF‐ κ B signaling in aortic focal, which further mitigates local inflammation and disease development. Overall, this study confirms the universal anti‐atherosclerotic effect of fullerenes and provides a novel therapeutic mechanism via modulating intestinal barrier to attenuate atherosclerosis.
Public Health Implications of Drought in a Climate Change Context: A Critical Review
Authors: Coral Salvador, Raquel Nieto, Sergio M. Vicente-Serrano, Ricardo García-Herrera, Luis Gimeno, Ana M. Vicedo-Cabrera
Journal: Annual Review of Public Health (2023)

Extreme weather events are expected to increase due to climate change, which could pose an additional burden of morbidity and mortality. In recent decades, drought severity has increased in several regions around the world, affecting health by increasing the risk of water-, food-, and vector-borne diseases, malnutrition, cardiovascular and respiratory illness, mental health disorders, and mortality. Drought frequency and severity are expected to worsen across large regions as a result of a decrease in precipitation and an increase in temperature and atmospheric evaporative demand, posing a pressing challenge for public health. Variation in impacts among countries and communities is due to multiple factors, such as aging, socioeconomic status, access to health care, and gender, affecting population resilience. Integrative proactive action plans focused on risk management are required, and resources should be transferred to developing countries to reduce their vulnerability and risk.
Vaccines Targeting Gliomas: Antigens Matter
Authors: Michael Platten, Niklas Grassl
Journal: Journal of Clinical Oncology (2023)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. December 15, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.02616 Journal of Clinical Oncology - published online before print January 9, 2023 PMID: 36623232 Vaccines Targeting Gliomas: Antigens Matter Michael Platten , MD1,2,3,4xMichael PlattenSearch for articles by this author and Niklas Grassl, MD1,2,4xNiklas GrasslSearch for articles by this author Show More 1DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany2Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany3Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany4DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany https://doi.org/10.1200/JCO.22.02616 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Michael PlattenCollection and assembly of data: Niklas GrasslManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTVaccines Targeting Gliomas: Antigens MatterThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael PlattenStock and Other Ownership Interests: EvotechConsulting or Advisory Role: Novartis (Inst), Monte Rosa Therapeutics (Inst)Research Funding: Bayer (Inst), Merck (Inst), Pfizer (Inst), Novartis (Inst), Roche/Genentech (Inst)Patents, Royalties, Other Intellectual Property: Diagnosing and treating IDH1-mutant cancers, treating H3.3K27M-mutant cancers, treating cancers with AHR antagonistsNo other potential conflicts of interest were reported. Companion Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial
Authors: Bruno Meduri, Antonella Baldissera, Cinzia Iotti, Luc J.E.E. Scheijmans, Marcel R. Stam, Salvatore Parisi, Liesbeth J. Boersma, Ilario Ammendolia, Eveline Koiter, Mariacarla Valli, Luciano Scandolaro, Dianne Busz, Marika C. Stenfert Kroese, Selena Ciabatti, Patrizia Giacobazzi, Maria P. Ruggieri, Antoine Engelen, Tindara Munafò, A. Helen Westenberg, Karolien Verhoeven, Roberto Vicini, Roberto D'Amico, Frank Lohr, Filippo Bertoni, Philip Poortmans, Giovanni P. Frezza
Journal: Journal of Clinical Oncology (2023)

The results in terms of side effects vary among the published accelerated partial-breast irradiation (APBI) studies. Here, we report the 5-year results for cosmetic outcomes and toxicity of the IRMA trial.We ran this randomized phase III trial in 35 centers. Women with stage I-IIA breast cancer treated with breast-conserving surgery, age ≥ 49 years, were randomly assigned 1:1 to receive either whole-breast irradiation (WBI) or external beam radiation therapy APBI (38.5 Gy/10 fraction twice daily). Patients and investigators were not masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence. We hereby present the analysis of the secondary outcomes, cosmesis, and normal tissue toxicity. All side effects were graded with the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Radiation Morbidity Scoring Schema. Analysis was performed with both intention-to-treat and as-treated approaches.Between March 2007 and March 2019, 3,309 patients were randomly assigned to 1,657 WBI and 1,652 APBI; 3,225 patients comprised the intention-to-treat population (1,623 WBI and 1,602 APBI). At a median follow-up of 5.6 (interquartile range, 4.0-8.4) years, adverse cosmesis in the APBI patients was higher than that in the WBI patients at 3 years (12.7% v 9.2%; P = .009) and at 5 years (14% v 9.8%; P = .012). Late soft tissue toxicity (grade ≥ 3: 2.8% APBI v 1% WBI, P < .0001) and late bone toxicity (grade ≥ 3: 1.1% APBI v 0% WBI, P < .0001) were significantly higher in the APBI arm. There were no significant differences in late skin and lung toxicities.External beam radiation therapy-APBI with a twice-daily IRMA schedule was associated with increased rates of late moderate soft tissue and bone toxicities, with a slight decrease in patient-reported cosmetic outcomes at 5 years when compared with WBI, although overall toxicity was in an acceptable range.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Authors: Eric A F Simões, Shabir A Madhi, William J Muller, Victoria Atanasova, Miroslava Bosheva, Fernando Cabañas, Manuel Baca Cots, Joseph B Domachowske, Maria L Garcia-Garcia, Ineta Grantina, Kim A Nguyen, Heather J Zar, Anna Berglind, Celeste Cummings, M Pamela Griffin, Therese Takas, Yuan Yuan, Ulrika Wählby Hamrén, Amanda Leach, Tonya Villafana
Journal: The Lancet Child & Adolescent Health (2023)
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non–Small-Cell Lung Cancer?
Authors: Ziming Li, Shun Lu
Journal: Journal of Clinical Oncology (2023)

The standard of care for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) without targetable mutations has recently shifted from chemotherapy to immunotherapy-based regimens; in current clinical practice, immunotherapy with or without chemotherapy is generally determined by the level of programmed death ligand 1 (PD-L1) expression on the tumor.Clinically, there are multiple immunotherapy combinations available, and the clinical challenge is selecting the appropriate combination in the absence of comparative trials.2][3][4][5] Immunotherapy plus chemotherapy is an approved regimen for both nonsquamous and squamous NSCLC regardless of tumor PD-L1 expression levels. 2,3Considering the recently reported 5-year overall survival (OS) results for pembrolizumab or pembrolizumab plus chemotherapy as first-line treatment in patients with advanced NSCLC (KEYNOTE 024-31.9%for patients with PD-L1 $ 50%, KEYNOTE 042-21.9%for patients with PD-L1 $ 50%, KEYNOTE 189-19.4% for patients with nonsquamous histology, and KEYNOTE 407-18.4% for patients with squamous histology), 5-8 it will be essential to understand the potential long-term benefits of adding a cytotoxic T-lymphocyte-associated protein 4 inhibitor to a programmed death 1 inhibitor.CheckMate 227 was a phase III, open-label, randomized controlled trial that enrolled treatment-naive patients with stage IV/recurrent NSCLC without EGFR mutations or ALK alterations (N 5 1739; Table 1).Patients with tumor PD-L1 $ 1% were randomly assigned to first-line nivolumab plus ipilimumab, nivolumab alone, or chemotherapy.Patients with tumor PD-L1 , 1% were randomly assigned to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. 9Brahmer et al 10 report the updated results of OS for part 1 of CheckMate 227 in this issue of the JCO.After a minimum follow-up of 61.3 months, 5-year OS rates were 24% versus 14% for nivolumab plus ipilimumab versus chemotherapy (PD-L1 $ 1%) and 19% versus 7% (PD-L1 , 1%).The median duration of response was 24.5 months compared with 6.7 months (PD-L1 $ 1%) and 19.4 months to 4.8 months (PD-L1 , 1%).Among patients surviving 5 years, 66% (PD-L1 $ 1%) and 64% (PD-L1 , 1%) were off nivolumab plus ipilimumab without initiating subsequent systemic anticancer treatment by the 5-year time point.The survival benefit persisted after discontinuation of nivolumab plus ipilimumab because of treatment-related adverse events (TRAE), with a 5-year OS rate of 39% (PD-L1 $ 1% and , 1% populations combined).
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
Authors: Yichao Hua, Gerlanda Vella, Florian Rambow, Elizabeth Allen, Asier Antoranz Martinez, Marie Duhamel, Akira Takeda, Sirpa Jalkanen, Steffie Junius, Ann Smeets, David Nittner, Stefanie Dimmeler, Thomas Hehlgans, Adrian Liston, Francesca Maria Bosisio, Giuseppe Floris, Damya Laoui, Maija Hollmén, Diether Lambrechts, Pascal Merchiers, Jean-Christophe Marine, Susan Schlenner, Gabriele Bergers
Journal: Cancer Cell (2023)

(Cancer Cell 40, 1600–1618; December 12, 2022) In this article, the authors demonstrated that antiangiogenic immunotherapies differentiate postcapillary venules into high-endothelial venules (HEVs) that foster permissive TCF1+ T lymphocyte niches. In the introduction, they mistakenly stated that HEVs express L-Selectin/CD62L, while HEVs express the sulphated and glycosylated ligands for L-Selectin/CD62L. The original article has been corrected online. The authors regret this error and apologize for any confusion this might have caused. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loopHua et al.Cancer CellNovember 23, 2022In BriefHua et al. reveal that effective antiangiogenic immunotherapy differentiates postcapillary venules into high-endothelial venules (HEVs) by lymphotoxin beta receptor activation emanating from CD8 T and NK cell-derived signals. TU-HEVs establish perivascular niches in which TCF1+PD1+ lymphocytes expand and produce cytotoxic PD1+TIM3+ lymphocytes that may facilitate anti-tumoral immunity. Full-Text PDF Open Access
The Benefit-Risk Ratio of Late Preterm Antenatal Corticosteroids Could Be Unfavorable in Real-life Situations
Authors: Thomas Schmitz, Marie-Victoire Sénat, Loic Sentilhes
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Human cortical interneurons optimized for grafting specifically integrate, abort seizures, and display prolonged efficacy without over-inhibition
Authors: Qian Zhu, Akanksha Mishra, Joy S. Park, Dongxin Liu, Derek T. Le, Sasha Z. Gonzalez, Morgan Anderson-Crannage, James M. Park, Gun-Hoo Park, Laura Tarbay, Kamron Daneshvar, Matthew Brandenburg, Christina Signoretti, Amy Zinski, Edward-James Gardner, Kelvin L. Zheng, Chiderah P. Abani, Carla Hu, Cameron P. Beaudreault, Xiao-Lei Zhang, Patric K. Stanton, Jun-Hyeong Cho, Libor Velíšek, Jana Velíšková, Saqlain Javed, Christopher S. Leonard, Hae-Young Kim, Sangmi Chung
Journal: Neuron (2023)
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis
Authors: Karan Sud, Navneet Narula, Elena Aikawa, Eloisa Arbustini, Philippe Pibarot, Giampaolo Merlini, Robert S. Rosenson, Surya V. Seshan, Edgar Argulian, Amir Ahmadi, Fang Zhou, Andre L. Moreira, Nancy Côté, Sotirios Tsimikas, Valentin Fuster, Sam Gandy, Robert O. Bonow, Olga Gursky, Jagat Narula
Journal: Nature Reviews Cardiology (2023)
Personal strategies to mitigate the effects of air pollution exposure during sport and exercise: a narrative review and position statement by the Canadian Academy of Sport and Exercise Medicine and the Canadian Society for Exercise Physiology
Authors: Andy Hung, Sarah Koch, Valerie Bougault, Cameron Marshall Gee, Romulo Bertuzzi, Malindi Elmore, Paddy McCluskey, Laura Hidalgo, Judith Garcia-Aymerich, Michael Stephen Koehle
Journal: British Journal of Sports Medicine (2023)

Air pollution is among the leading environmental threats to health around the world today, particularly in the context of sports and exercise. With the effects of air pollution, pollution episodes (eg, wildfire conflagrations) and climate change becoming increasingly apparent to the general population, so have their impacts on sport and exercise. As such, there has been growing interest in the sporting community (ie, athletes, coaches, and sports science and medicine team members) in practical personal-level actions to reduce the exposure to and risk of air pollution. Limited evidence suggests the following strategies may be employed: minimising all exposures by time and distance, monitoring air pollution conditions for locations of interest, limiting outdoor exercise, using acclimation protocols, wearing N95 face masks and using antioxidant supplementation. The overarching purpose of this position statement by the Canadian Academy of Sport and Exercise Medicine and the Canadian Society for Exercise Physiology is to detail the current state of evidence and provide recommendations on implementing these personal strategies in preventing and mitigating the adverse health and performance effects of air pollution exposure during exercise while recognising the limited evidence base.
The Kaposi’s sarcoma progenitor enigma: KSHV-induced MEndT–EndMT axis
Authors: Julian Naipauer, Enrique A. Mesri
Journal: Trends in Molecular Medicine (2023)

Endothelial-to-mesenchymal transition has been described in tumors as a source of mesenchymal stroma, while the reverse process has been proposed in tumor vasculogenesis and angiogenesis. A human oncogenic virus, Kaposi's sarcoma herpes virus (KSHV), can regulate both processes in order to transit through this transition 'boulevard' when infecting KS oncogenic progenitor cells. Endothelial or mesenchymal circulating progenitor cells can serve as KS oncogenic progenitors recruited by inflammatory cytokines because KSHV can reprogram one into the other through endothelial-to-mesenchymal and mesenchymal-to-endothelial transitions. Through these novel insights, the identity of the potential oncogenic progenitor of KS is revealed while gaining knowledge of the biology of the mesenchymal-endothelial differentiation axis and pointing to this axis as a therapeutic target in KS.
Bioactive glass-elicited stem cell-derived extracellular vesicles regulate M2 macrophage polarization and angiogenesis to improve tendon regeneration and functional recovery
Authors: Hongtao Xu, Yanlun Zhu, Allen Wei-Ting Hsiao, Jiankun Xu, Wenxue Tong, Liang Chang, Xuerao Zhang, Yi-Fan Chen, Jie Li, Wei Chen, Yingze Zhang, Hon Fai Chan, Chien-Wei Lee
Journal: Biomaterials (2023)
Computer-aided diagnosis for optical diagnosis of diminutive colorectal polyps including sessile serrated lesions: a real-time comparison with screening endoscopists
Authors: Britt B. S. L. Houwen, Yark Hazewinkel, Ioannis Giotis, Jasper L. A. Vleugels, Nahid S. Mostafavi, Paul van Putten, Paul Fockens, Evelien Dekker
Journal: Endoscopy (2023)

BACKGROUND : We aimed to compare the accuracy of the optical diagnosis of diminutive colorectal polyps, including sessile serrated lesions (SSLs), between a computer-aided diagnosis (CADx) system and endoscopists during real-time colonoscopy. METHODS : We developed the POLyp Artificial Recognition (POLAR) system, which was capable of performing real-time characterization of diminutive colorectal polyps. For pretraining, the Microsoft-COCO dataset with over 300 000 nonpolyp object images was used. For training, eight hospitals prospectively collected 2637 annotated images from 1339 polyps (i. e. publicly available online POLAR database). For clinical validation, POLAR was tested during colonoscopy in patients with a positive fecal immunochemical test (FIT), and compared with the performance of 20 endoscopists from eight hospitals. Endoscopists were blinded to the POLAR output. Primary outcome was the comparison of accuracy of the optical diagnosis of diminutive colorectal polyps between POLAR and endoscopists (neoplastic [adenomas and SSLs] versus non-neoplastic [hyperplastic polyps]). Histopathology served as the reference standard. RESULTS : During clinical validation, 423 diminutive polyps detected in 194 FIT-positive individuals were included for analysis (300 adenomas, 41 SSLs, 82 hyperplastic polyps). POLAR distinguished neoplastic from non-neoplastic lesions with 79 % accuracy, 89 % sensitivity, and 38 % specificity. The endoscopists achieved 83 % accuracy, 92 % sensitivity, and 44 % specificity. The optical diagnosis accuracy between POLAR and endoscopists was not significantly different (
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Authors: Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, Nancy L. DiFronzo, Erica B. Esrick, Joshua J. Field, Courtney D. Fitzhugh, Julie Kanter, Neena Kapoor, Donald B. Kohn, Lakshmanan Krishnamurti, Wendy B. London, Michael A. Pulsipher, Sohel Talib, Alexis A. Thompson, Edmund K. Waller, Ted Wun, Mary M. Horowitz
Journal: Journal of Clinical Oncology (2023)

To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease.
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
Authors: Kaysia Ludford, Won Jin Ho, Jane V. Thomas, Kanwal P.S. Raghav, Mariela Blum Murphy, Nicole D. Fleming, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar, Arvind Dasari, Sarah Shin, Alexei Hernandez, Xuan Yuan, Hongqui Yang, Wai Chin Foo, Wei Qiao, Dipen Maru, Scott Kopetz, Michael J. Overman
Journal: Journal of Clinical Oncology (2023)

Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space.
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features
Authors: Victoria Holdstock, Jonathan Twynam-Perkins, Timothy Bradnock, Elizabeth M Dickson, Kathleen Harvey-Wood, Pota Kalima, Jill King, William J Olver, Mustafa Osman, Atul Sabharwal, Andrew Smith, Stefan Unger, Louisa Pollock, Ross Langley, Philip Davies, Thomas C Williams
Journal: The Lancet Infectious Diseases (2023)